ILDR2

Summary

ILDR2 (immunoglobulin like domain containing receptor 2, HGNC:18131) is a protein-coding gene on chromosome 1q24.1, encoding Immunoglobulin-like domain-containing receptor 2 (Q71H61). May be involved in ER stress pathways with effects on lipid homeostasis and insulin secretion.

Involved in negative regulation of T cell activation. Predicted to be located in tight junction. Predicted to be active in membrane.

Source: NCBI Gene 387597 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 103 total — 1 likely-pathogenic
• Phenotypes (HPO): 1
• MANE Select transcript: NM_199351

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18131
Approved symbol	ILDR2
Name	immunoglobulin like domain containing receptor 2
Location	1q24.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000143195
Ensembl biotype	protein_coding
OMIM	618081
Entrez	387597

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 8 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000271417, ENST00000414590, ENST00000469934, ENST00000525740, ENST00000526687, ENST00000528703, ENST00000529071, ENST00000529387, ENST00000614979, ENST00000880432

RefSeq mRNA: 3 — MANE Select: NM_199351 NM_001410891, NM_001410892, NM_199351

CCDS: CCDS1256, CCDS91097, CCDS91098

Canonical transcript exons

ENST00000271417 — 10 exons

Exon	Start	End
ENSE00000958594	166957769	166958101
ENSE00000958595	166956733	166956852
ENSE00000958596	166936591	166936737
ENSE00000958597	166927067	166927180
ENSE00001367803	166920707	166921379
ENSE00001371788	166935301	166935477
ENSE00001375693	166922593	166922809
ENSE00001376217	166908187	166919390
ENSE00001381197	166939514	166939570
ENSE00001403958	166975223	166975540

Expression profiles

Bgee: expression breadth ubiquitous, 182 present calls, max score 90.74.

FANTOM5 (CAGE): breadth broad, TPM avg 2.5280 / max 83.7260, expressed in 427 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
15752	1.2617	341
15751	0.9259	305
15750	0.2871	166
15749	0.0533	28

Top tissues by expression

248 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
oocyte	CL:0000023	90.74	gold quality
kidney epithelium	UBERON:0004819	89.67	silver quality
germinal epithelium of ovary	UBERON:0001304	89.35	gold quality
secondary oocyte	CL:0000655	89.16	gold quality
endothelial cell	CL:0000115	85.43	gold quality
sperm	CL:0000019	84.81	gold quality
primary visual cortex	UBERON:0002436	84.03	gold quality
left ventricle myocardium	UBERON:0006566	83.54	gold quality
Brodmann (1909) area 23	UBERON:0013554	83.00	gold quality
anterior cingulate cortex	UBERON:0009835	81.61	gold quality
prefrontal cortex	UBERON:0000451	81.02	gold quality
Brodmann (1909) area 9	UBERON:0013540	80.80	gold quality
middle temporal gyrus	UBERON:0002771	80.71	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	80.49	gold quality
amygdala	UBERON:0001876	80.47	gold quality
right frontal lobe	UBERON:0002810	80.47	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	80.11	gold quality
tendon of biceps brachii	UBERON:0008188	80.03	silver quality
neocortex	UBERON:0001950	79.62	gold quality
pancreatic ductal cell	CL:0002079	79.54	silver quality
frontal cortex	UBERON:0001870	79.38	gold quality
occipital lobe	UBERON:0002021	78.69	gold quality
cerebral cortex	UBERON:0000956	78.67	gold quality
parietal pleura	UBERON:0002400	78.21	gold quality
temporal lobe	UBERON:0001871	77.46	gold quality
hypothalamus	UBERON:0001898	77.11	gold quality
lateral nuclear group of thalamus	UBERON:0002736	76.68	gold quality
testis	UBERON:0000473	76.23	gold quality
superior frontal gyrus	UBERON:0002661	76.23	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	76.20	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.80

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

333 targeting ILDR2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-432-3P	100.00	67.86	705
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-3120-5P	100.00	65.56	965
HSA-MIR-6748-5P	100.00	65.81	1057
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-1193	100.00	65.93	529
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-3925-3P	100.00	69.95	1237
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833

Literature-anchored findings (GeneRIF, showing 1)

• We demonstrated that ZNF70 interacts with ZFP64 and activates HES1 transcription by binding to the HES1 promoter. In addition, HES1 gene expression is increased in ILDR2-knockdown HepG2 cells, in which ZNF70 is translocated from the cytoplasm to the nucleus, suggesting that ZNF70 migration to the nucleus after dissociating from the ILDR2-ZNF70 complex activates HES1 transcription. These results support a novel link betwee (PMID:27353377)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	ildr2	ENSDARG00000014180
danio_rerio	si:zfos-1011f11.2	ENSDARG00000101073
mus_musculus	Ildr2	ENSMUSG00000040612
rattus_norvegicus	Ildr2	ENSRNOG00000025151

Paralogs (2): LSR (ENSG00000105699), ILDR1 (ENSG00000145103)

Protein

Protein identifiers

Immunoglobulin-like domain-containing receptor 2 — Q71H61 (reviewed: Q71H61)

Alternative names: Angulin-3

All UniProt accessions (7): Q71H61, E9PLS0, E9PNU3, E9PPL0, E9PQC8, E9PR23, E9PRA4

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in ER stress pathways with effects on lipid homeostasis and insulin secretion. With ILDR1 and LSR, involved in the maintain of the epithelial barrier function through the recruitment of MARVELD2/tricellulin to tricellular tight junctions. Also functions as a B7-like protein family member expressed on immune cells and inflamed tissue and with T-cell inhibitory activity. In the inner ear, may regulate alternative pre-mRNA splicing via binding to TRA2A, TRA2B and SRSF1.

Subunit / interactions. Interacts with MARVELD2 and OCLN. Interacts with P4HB AND HSPA5; the interaction with HSPA5 stabilizes ILDR2 expression. Interacts (via C-terminus) with TRA2A, TRA2B and SRSF1.

Subcellular location. Endoplasmic reticulum membrane. Cell junction. Tight junction. Nucleus.

Tissue specificity. Expressed in testis, brain, pituitary, colon, heart, nerves, prostate, esophagus, lung liver and small intestine. Highly expressed in macrophages, also expressed in monocytes and at low levels in NK and NKT cells (at protein level).

Similarity. Belongs to the immunoglobulin superfamily. LISCH7 family.

RefSeq proteins (3): NP_001397820, NP_001397821, NP_955383* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003599	Ig_sub	Domain
IPR008664	LISCH7	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR051874	Ig-like_domain-LISCH7	Family

Pfam: PF05624

UniProt features (18 total): compositionally biased region 4, modified residue 3, region of interest 3, topological domain 2, signal peptide 1, chain 1, disulfide bond 1, sequence variant 1, transmembrane region 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q71H61-F1	56.70	0.16

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 473, 544, 579

Disulfide bonds (1): 42–145

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 168 (showing top): GOBP_REGULATION_OF_CELL_ACTIVATION, BENPORATH_ES_WITH_H3K27ME3, GOBP_INSULIN_SECRETION, GOBP_REGULATION_OF_HORMONE_LEVELS, GOBP_NEGATIVE_REGULATION_OF_CELL_CELL_ADHESION, GOBP_HORMONE_TRANSPORT, GOBP_CELL_CELL_SIGNALING, GOBP_PANCREAS_DEVELOPMENT, TERAMOTO_OPN_TARGETS_CLUSTER_5, GOBP_CELL_CELL_ADHESION, GOBP_NEGATIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS, GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOBP_RNA_SPLICING, GOBP_SECRETION, TGANTCA_AP1_C

GO Biological Process (7): response to glucose (GO:0009749), insulin secretion (GO:0030073), cell differentiation (GO:0030154), pancreas development (GO:0031016), regulation of RNA splicing (GO:0043484), homeostasis of number of cells within a tissue (GO:0048873), negative regulation of T cell activation (GO:0050868)

GO Molecular Function (0):

GO Cellular Component (8): nucleus (GO:0005634), endoplasmic reticulum membrane (GO:0005789), bicellular tight junction (GO:0005923), membrane (GO:0016020), tight junction (GO:0070160), endoplasmic reticulum (GO:0005783), endomembrane system (GO:0012505), anchoring junction (GO:0070161)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular membrane-bounded organelle	2
cellular anatomical structure	2
response to hexose	1
protein secretion	1
peptide hormone secretion	1
cellular developmental process	1
animal organ development	1
RNA splicing	1
regulation of gene expression	1
regulation of primary metabolic process	1
tissue homeostasis	1
homeostasis of number of cells	1
T cell activation	1
regulation of T cell activation	1
negative regulation of lymphocyte activation	1
negative regulation of leukocyte cell-cell adhesion	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
apical junction complex	1
tight junction	1
cell-cell junction	1
cytoplasm	1
endomembrane system	1
vacuole	1
plasma membrane	1
cell junction	1

Protein interactions and networks

STRING

651 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ILDR2	MARVELD2	Q8N4S9	893
ILDR2	TRA2A	Q13595	581
ILDR2	OCLN	Q16625	559
ILDR2	POGK	Q9P215	511
ILDR2	ZFP69	Q49AA0	506
ILDR2	TRA2B	P62995	499
ILDR2	LSR	Q86X29	463
ILDR2	IGSF5	Q9NSI5	455
ILDR2	J3KSM2	J3KSM2	407
ILDR2	SRSF1	Q07955	373
ILDR2	SORCS1	Q8WY21	370
ILDR2	DNAJC24	Q6P3W2	360
ILDR2	SRRM4	A7MD48	359
ILDR2	SFSWAP	Q12872	353
ILDR2	CLDN9	O95484	343

IntAct

18 interactions, top by confidence:

A	B	Type	Score
CHRNA4	FZD6	psi-mi:“MI:0914”(association)	0.530
EVA1C	STK25	psi-mi:“MI:0914”(association)	0.530
HFE	ADAM10	psi-mi:“MI:0914”(association)	0.530
PCDHAC2	TMEM223	psi-mi:“MI:0914”(association)	0.530
ILDR2	H1-2	psi-mi:“MI:0915”(physical association)	0.400
H1-5	ILDR2	psi-mi:“MI:0915”(physical association)	0.400
SFN	ILDR2	psi-mi:“MI:0915”(physical association)	0.400
CHRNA4	TMEM223	psi-mi:“MI:0914”(association)	0.350
ADGRG5	SLC33A1	psi-mi:“MI:0914”(association)	0.350
CHRNB1	CLGN	psi-mi:“MI:0914”(association)	0.350
CLEC2D	ATP9A	psi-mi:“MI:0914”(association)	0.350
GRAMD1B	MYCBP2	psi-mi:“MI:0914”(association)	0.350
KIRREL1	TNFRSF1A	psi-mi:“MI:0914”(association)	0.350
LRRC52	DYSF	psi-mi:“MI:0914”(association)	0.350
SFTPC	CYTH3	psi-mi:“MI:0914”(association)	0.350
TMED5	DGAT1	psi-mi:“MI:0914”(association)	0.350
KCNJ2	PIK3R2	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (61): ILDR2 (Proximity Label-MS), ILDR2 (Proximity Label-MS), ILDR2 (Proximity Label-MS), ILDR2 (Proximity Label-MS), ILDR2 (Proximity Label-MS), ILDR2 (Proximity Label-MS), ILDR2 (Proximity Label-MS), ILDR2 (Proximity Label-MS), ILDR2 (Proximity Label-MS), ILDR2 (Proximity Label-MS), ILDR2 (Proximity Label-MS), ILDR2 (Proximity Label-MS), ILDR2 (Proximity Label-MS), ILDR2 (Proximity Label-MS), ILDR2 (Proximity Label-MS)

ESM2 similar proteins: A0A1L8H8C0, A0A1L8HFX9, A2CEX1, A2RUV4, A4V8B4, A8XU52, C5DGS4, C5DT56, E7KIY3, E9QDC5, F1QPR4, G5EEK3, H2L045, O60504, P27715, Q02645, Q02831, Q11181, Q32NM7, Q3U5C7, Q571K4, Q5T5U3, Q5U303, Q60JJ0, Q6DFG0, Q6DFV3, Q71H61, Q71M21, Q71QF9, Q7Z3G6, Q7ZXH3, Q80Y24, Q86SQ0, Q8BRG8, Q8K1N2, Q8N5C8, Q8NEY8, Q8VEB2, Q96MT3, Q96SK2

Diamond homologs: B5TVM2, Q32NM7, Q5R8C7, Q71H61, Q86SU0, Q86X29, Q8CBR1, Q99KG5, Q9WU74

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

103 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	93
Likely benign	1
Benign	1

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
982219	NM_199351.3(ILDR2):c.1049G>A (p.Arg350His)	Likely pathogenic

SpliceAI

1585 predictions. Top by Δscore:

Variant	Effect	Δscore
1:166921376:CTGG:C	acceptor_gain	1.0000
1:166921377:TGG:T	acceptor_gain	1.0000
1:166921380:C:CC	acceptor_gain	1.0000
1:166922394:TCTAC:T	donor_gain	1.0000
1:166922738:T:C	donor_gain	1.0000
1:166927066:CAT:C	donor_gain	1.0000
1:166927079:T:TA	donor_gain	1.0000
1:166956727:ACTT:A	donor_loss	1.0000
1:166956730:TACCC:T	donor_loss	1.0000
1:166956731:A:AC	donor_gain	1.0000
1:166956731:A:T	donor_loss	1.0000
1:166956731:AC:A	donor_gain	1.0000
1:166956732:C:CC	donor_gain	1.0000
1:166956732:C:G	donor_loss	1.0000
1:166956732:CC:C	donor_gain	1.0000
1:166956732:CCCAA:C	donor_gain	1.0000
1:166956852:TC:T	acceptor_loss	1.0000
1:166956853:C:CC	acceptor_gain	1.0000
1:166956853:C:T	acceptor_loss	1.0000
1:166956854:T:A	acceptor_loss	1.0000
1:166957841:C:CT	donor_gain	1.0000
1:166957842:T:TT	donor_gain	1.0000
1:166958098:ATGG:A	acceptor_gain	1.0000
1:166958099:TGG:T	acceptor_gain	1.0000
1:166975218:CTTAC:C	donor_loss	1.0000
1:166975219:TTAC:T	donor_loss	1.0000
1:166975220:TAC:T	donor_loss	1.0000
1:166975221:ACCTG:A	donor_loss	1.0000
1:166975222:C:CT	donor_loss	1.0000
1:166919197:C:CA	donor_gain	0.9900

AlphaMissense

4172 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:166927114:T:A	E316V	1.000
1:166927117:A:T	V315D	1.000
1:166956821:C:A	W137C	1.000
1:166956821:C:G	W137C	1.000
1:166956843:A:G	L130P	1.000
1:166957980:C:A	W56C	1.000
1:166957980:C:G	W56C	1.000
1:166957982:A:G	W56R	1.000
1:166957982:A:T	W56R	1.000
1:166927105:A:G	L319P	0.999
1:166927113:C:A	E316D	0.999
1:166927113:C:G	E316D	0.999
1:166936603:A:G	C231R	0.999
1:166936630:A:G	C222R	0.999
1:166956744:A:G	L163P	0.999
1:166956797:A:C	C145W	0.999
1:166956798:C:G	C145S	0.999
1:166956798:C:T	C145Y	0.999
1:166956799:A:G	C145R	0.999
1:166956799:A:T	C145S	0.999
1:166956823:A:G	W137R	0.999
1:166956823:A:T	W137R	0.999
1:166956843:A:T	L130H	0.999
1:166957837:G:T	A104D	0.999
1:166957838:C:G	A104P	0.999
1:166957963:C:G	C62S	0.999
1:166957964:A:T	C62S	0.999
1:166957981:C:G	W56S	0.999
1:166927105:A:T	L319Q	0.998
1:166927114:T:G	E316A	0.998

dbSNP variants (sampled 300 via entrez): RS1000021756 (1:166913648 A>G), RS1000036681 (1:166970643 C>T), RS1000067127 (1:166943309 A>C,G), RS1000115204 (1:166950847 G>A,T), RS1000263075 (1:166920030 G>A,T), RS1000310 (1:166926263 T>C), RS1000334095 (1:166921535 T>A,C), RS1000336100 (1:166909780 T>A,C), RS1000353046 (1:166958636 G>A), RS1000391234 (1:166965797 T>C,G), RS1000437109 (1:166965576 T>TG), RS1000488509 (1:166948042 A>C,G), RS1000493302 (1:166914950 T>C), RS1000503112 (1:166908525 C>T), RS1000541511 (1:166971153 C>T)

Disease associations

OMIM: gene MIM:618081 | disease phenotypes: MIM:209850

GenCC curated gene-disease

Mondo (1): autism (MONDO:0005260)

Orphanet (1): Moyamoya angiopathy (Orphanet:477768)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000717	Autism

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST010697_48	Cortical surface area (min-P)	3.000000e-13
GCST010698_42	Subcortical volume (min-P)	8.000000e-12
GCST010699_55	Brain morphology (min-P)	2.000000e-40
GCST010700_39	Cortical thickness (MOSTest)	4.000000e-08
GCST010701_100	Cortical surface area (MOSTest)	1.000000e-12
GCST010702_40	Subcortical volume (MOSTest)	2.000000e-10
GCST010703_26	Brain morphology (MOSTest)	5.000000e-09

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004346	neuroimaging measurement
EFO:0004840	cortical thickness

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D001321	Autistic Disorder	F03.625.164.113.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other protein — Other immune checkpoint proteins

CTD chemical–gene interactions

21 total (human), top 21 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, increases expression, increases methylation	5
trichostatin A	decreases expression, affects cotreatment	2
sodium arsenite	decreases expression, increases expression	2
entinostat	decreases expression, affects cotreatment	2
Cadmium Chloride	increases expression, decreases expression	2
FR900359	decreases phosphorylation	1
nickel sulfate	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
nutlin 3	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Atrazine	increases expression	1
Camptothecin	increases expression	1
Cisplatin	increases expression	1
Dactinomycin	affects cotreatment, increases expression	1
Doxorubicin	decreases expression	1
Methotrexate	increases expression	1
Methyl Methanesulfonate	increases expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Triclosan	decreases expression	1
Vincristine	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00211796	PHASE4	COMPLETED	Divalproex Sodium ER in Adult Autism
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT00409747	PHASE4	COMPLETED	Minocycline to Treat Childhood Regressive Autism
NCT00576732	PHASE4	COMPLETED	A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder
NCT00844753	PHASE4	COMPLETED	Atomoxetine, Placebo and Parent Management Training in Autism
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01098383	PHASE4	UNKNOWN	Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02069977	PHASE4	UNKNOWN	Study to Evaluate the Efficacy and Safety of Aripiprazole
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02199925	PHASE4	UNKNOWN	An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02255565	PHASE4	COMPLETED	Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT00036231	PHASE3	TERMINATED	Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction
NCT00036244	PHASE3	COMPLETED	Synthetic Human Secretin in Children With Autism
NCT00065884	PHASE3	UNKNOWN	Valproate Response in Aggressive Autistic Adolescents
NCT00065962	PHASE3	COMPLETED	Secretin for the Treatment of Autism
NCT00252603	PHASE3	COMPLETED	Galantamine Versus Placebo in Childhood Autism
NCT00346736	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00352248	PHASE3	COMPLETED	Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autistic Spectrum Disorder
NCT00352352	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00355329	PHASE3	COMPLETED	Randomized Control Trial of Using Tongue Acupuncture in Autistic Spectrum Disorder Using PET Scan for Clinical Correlation
NCT00498173	PHASE3	COMPLETED	Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism
NCT00541346	PHASE3	COMPLETED	A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms